Pasar al contenido principal

GENERACION DE NUEVOS AGENTES TERAPEUTICOS PARA BLOQUER LA TRANSMISION DEL VIH-1 ENTRE CELULAS MEDIADA POR LAS CELULAS DENDRITICAS

SAF2013-49042-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection

  • Martínez Bonet, Marta
  • González-Serna, Alejandro
  • Clemente, M. I.
  • Morón-López, S.
  • Díaz, Laura
  • Navarro Gómez, María Luisa
  • Puertas, M. C.
  • Leal, Manuel
  • Ruiz-Mateos, Ezequiel
  • Martínez-Picado, Javier
  • Muñoz-Fernández, María Ángeles
[Background] Several host factors contribute to human immunodeficiency virus (HIV) disease progression in the absence of combination antiretroviral therapy (cART). Among them, the CC-chemokine receptor 5 (CCR5) is known to be the main co-receptor used by HIV-1 to enter target cells during the early stages of an HIV-1 infection., [Objective] We evaluated the association of CCR5(WT/Δ32) heterozygosity with HIV-1 reservoir size, lymphocyte differentiation, activation and immunosenescence in adolescents and young adults with perinatally acquired HIV infection receiving cART. [Methods] CCR5 genotype was analysed in 242 patients with vertically transmitted HIV-1 infection from Paediatric Spanish AIDS Research Network Cohort (coRISpe). Proviral HIV-1 DNA was quantified by digital-droplet PCR, and T-cell phenotype was evaluated by flow cytometry in a subset of 24 patients (ten with CCR5(Δ32/WT) genotype and 14 with CCR5(WT/WT) genotype). [Results] Twenty-three patients were heterozygous for the Δ32 genotype but none was homozygous for the mutated CCR5 allele. We observed no difference in the HIV-1 reservoir size (455 and 578 copies of HIV-1 DNA per million CD4+ T cells in individuals with CCR5(WT/WT) and CCR5(Δ32/WT) genotypes, respectively; p 0.75) or in the immune activation markers between both genotype groups. However, we found that total HIV-1 DNA in CD4+ T cells correlated with the percentage of memory CD4+ T cells: a direct correlation in CCR5(WT/Δ32) patients but an inverse correlation in those with the CCR5(WT/WT) genotype. [Conclusions] This finding suggests a differential distribution of the viral reservoir compartment in CCR5(WT/Δ32) patients with perinatal HIV infection, which is a characteristic that may affect the design of strategies for reservoir elimination., We particularly acknowledge the Spanish HIV HGM BioBank supported by the Spanish Instituto de Salud Carlos III, which is integrated with the Spanish AIDS Research Network. We thank V. Urrea (AIDS Research Institute IrsiCaixa, Badalona) for statistical support. IrsiCaixa is supported by the CERCA programme from Generalitat de Catalunya. Work by the group of MAMF was supported by Instituto de Salud Carlos III (Subdirección General de Evaluación) and Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT13/0010/0028, Fondo de Investigacion Sanitaria (FIS) (grants PI13/02016, PI12/0014 and CD14/00320 to AGS), Comunidad de Madrid (grant S-2010/BMD-2332]. This work was (partially) funded by the RD12/0017/0037 project as part of the Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008–2011 (HGUGM) and by CYTED 214RT0482. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. This project was also supported by the Spanish Secretariat of Research (grant Red Temática de Investigación Cooperativa en SIDA [RD12/0017] and CPII014/00025 and PI12/02283 from Fondo de Investigación Sanitaria (FIS) to E.R.-M.) Work by the JM-P group is supported by the Spanish Secretariat of Research (grant SAF2013-49042-R), the Foundation for AIDS Research (amfAR), and the Spanish AIDS network ‘Red Temática Cooperativa de Investigación en SIDA’ (RD12/0017/0002). S.M-L. was supported by Agència de Gestió d’Ajuts Universitaris i de Recerca from Generalitat de Catalunya (2013FI_B 00275).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

  • Molinos-Albert, Luis M
  • Bilbao, Eneritz
  • Agulló, Luis
  • Marfil, Silvia
  • García, Elisabet
  • Rodríguez de la Concepción, Maria Luisa
  • Izquierdo-Useros, Núria
  • Vilaplana, Cristina
  • Nieto-Garai, Jon Ander
  • Contreras, F. Xabier
  • Floor, Martin
  • Cardona, Pere J
  • Martínez-Picado, Javier
  • Clotet, Bonaventura
  • Villà-Freixa, Jordi
  • Lorizate, Maier
  • Carrillo, Jorge
  • Blanco, Julià
The HIV-1 gp41 Membrane Proximal External Region (MPER) is recognized by broadly neutralizing antibodies and represents a promising vaccine target. However, MPER immunogenicity and antibody activity are influenced by membrane lipids. To evaluate lipid modulation of MPER immunogenicity, we generated a 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC)-based proteoliposome collection containing combinations of phosphatidylserine (PS), GM3 ganglioside, cholesterol (CHOL), sphingomyelin (SM) and the TLR4 agonist monophosphoryl lipid A (MPLA). A recombinant gp41-derived miniprotein (gp41-MinTT) exposing the MPER and a tetanus toxoid (TT) peptide that favors MHC-II presentation, was successfully incorporated into lipid mixtures (>85%). Immunization of mice with soluble gp41-MinTT exclusively induced responses against the TT peptide, while POPC proteoliposomes generated potent anti-gp41 IgG responses using lower protein doses. The combined addition of PS and GM3 or CHOL/SM to POPC liposomes greatly increased gp41 immunogenicity, which was further enhanced by the addition of MPLA. Responses generated by all proteoliposomes targeted the N-terminal moiety of MPER overlapping the 2F5 neutralizing epitope. Our data show that lipids impact both, the epitope targeted and the magnitude of the response to membrane-dependent antigens, helping to improve MPER-based lipid carriers. Moreover, the identification of immunodominant epitopes allows for the redesign of immunogens targeting MPER neutralizing determinants., This work was supported by the HIVACAT Program, the CERCA Program (Generalitat de Catalunya), the Spanish AIDS network ‘Red Temática Cooperativa de Investigación en SIDA’ (RD12/0017/0002), the Fondo de Investigaciones Sanitarias and FEDER “Fondo Europeo de Desarrollo Regional” (grant number PI14/01307, to JB), the Basque Country Government (grant number IT838-13 to ML) and the Spanish Ministry of Economy (BFU2012-33103 to ML and FXC; and SAF2013-49042-R to JMP and NIU). The utilization of supercomputational facilities was supported by The Spanish Supercomputing Network (grant numbers BCV-2015-2-0009 and BCV-2016-2-0005). J.B. is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol supported by the Health Department of the Catalan Government (Generalitat de Catalunya). LMM-A was supported by an FI predoctoral grant from Agència de Gestió d’Ajuts Universitaris i de Recerca from Generalitat de Catalunya and European Social Fund. JAN is supported by an FI predoctoral fellowship from the Basque Government. CV receives support from ISCIII-Subdirección General de Evaluación and Fondo-EU de Desarrollo Regional (FEDER) contract CP13/00174., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

  • Molinos-Albert, Luis M.
  • Bilbao, Eneritz
  • Agulló, Luis
  • Marfil, Silvia
  • García, Elisabet
  • Rodríguez de la Concepción, Maria Luisa
  • Izquierdo-Useros, Nuria
  • Vilaplana, Cristina
  • Nieto-Garai, Jon A.
  • Contreras, F. Xabier
  • Floor, Martin
  • Cardona, Pere J.
  • Martinez-Picado, Javier
  • Clotet, Bonaventura
  • Villà-Freixa, Jordi
  • Lorizate, Maier
  • Carrillo, Jorge
  • Blanco, Julià
We are grateful to Jorge Díaz, Vanessa García and Ismael Varela from the Animal Facility of IGTP for excellent technical assistance. This work was supported by the HIVACAT Program, the CERCA Program (Generalitat de Catalunya), the Spanish AIDS network ‘Red Temática Cooperativa de Investigación en SIDA’ (RD12/0017/0002), the Fondo de Investigaciones Sanitarias and FEDER “Fondo Europeo de Desarrollo Regional” (grant number PI14/01307, to JB), the Basque Country Government (grant number IT838-13 to ML) and the Spanish Ministry of Economy (BFU2012-33103 to ML and FXC; and SAF2013-49042-R to JMP and NIU). The utilization of supercomputational facilities was supported by The Spanish Supercomputing Network (grant numbers BCV2015-2-0009 and BCV-2016-2-0005). J.B. is a researcher from Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol supported by the Health Department of the Catalan Government (Generalitat de Catalunya). LMM-A was supported by an FI predoctoral grant from Agència de Gestió d’Ajuts Universitaris i de Recerca from Generalitat de Catalunya and European Social Fund. JAN is supported by an FI predoctoral fellowship from the Basque Government. CV receives support from ISCIII-Subdirección General de Evaluación and Fondo-EU de Desarrollo Regional (FEDER) contract CP13/00174. CV and PJC are members of the CRP-TB (Group 17) of the Spanish Network CIBER Enfermedades Respiratorias. The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp41 Monoclonal (D50) (Cat# 11393); HIV-1 Consensus Subtype B Env Peptide Set (cat# 9480)., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells

  • Pino, Maria
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Benet, Susana|||0000-0002-2219-8826
  • Erikson, Elina
  • Fernández-Figueras, Maria Teresa|||0000-0002-2366-7110
  • Guerrero, Dolores
  • Dalmau, Judith|||0000-0001-7513-3711
  • Ouchi, Dan|||0000-0002-8630-152X
  • Rausell, Antonio
  • Ciuffi, Angela
  • Keppler, Oliver T.
  • Telenti, Amalio
  • Kräusslich, Hans-Georg|||0000-0002-8756-329X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Myeloid cells are key players in the recognition and response of the host against invading viruses. Paradoxically, upon HIV-1 infection, myeloid cells might also promote viral pathogenesis through trans-infection, a mechanism that promotes HIV-1 transmission to target cells via viral capture and storage. The receptor Siglec-1 (CD169) potently enhances HIV-1 trans-infection and is regulated by immune activating signals present throughout the course of HIV-1 infection, such as interferon α (IFNα). Here we show that IFNα-activated dendritic cells, monocytes and macrophages have an enhanced ability to capture and trans-infect HIV-1 via Siglec-1 recognition of viral membrane gangliosides. Monocytes from untreated HIV-1-infected individuals trans-infect HIV-1 via Siglec-1, but this capacity diminishes after effective antiretroviral treatment. Furthermore, Siglec-1 is expressed on myeloid cells residing in lymphoid tissues, where it can mediate viral trans-infection. Siglec-1 on myeloid cells could fuel novel CD4(+) T-cell infections and contribute to HIV-1 dissemination in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of Siglec-1 null individuals infected with HIV-1

  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • McLaren, Paul J.
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Martin, Maureen P.
  • Benet, Susana|||0000-0002-2219-8826
  • Rotger, Margalida
  • Dalmau, Judith|||0000-0001-7513-3711
  • Ouchi, Dan|||0000-0002-8630-152X
  • Wolinsky, Steven M.
  • Penugonda, Sudhir
  • Günthard, Huldrych F.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Carrington, Mary
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Telenti, Amalio
Siglec-1/CD169 is a myeloid-cell surface receptor critical for HIV-1 capture and infection of bystander target cells. To dissect the role of SIGLEC1 in natura, we scan a large population genetic database and identify a loss-of-function variant (Glu88Ter) that is found in ∼1% of healthy people. Exome analysis and direct genotyping of 4,233 HIV-1-infected individuals reveals two Glu88Ter homozygous and 97 heterozygous subjects, allowing the analysis of ex vivo and in vivo consequences of SIGLEC1 loss-of-function. Cells from these individuals are functionally null or haploinsufficient for Siglec-1 activity in HIV-1 capture and trans-infection ex vivo. However, Siglec-1 protein truncation does not have a measurable impact on HIV-1 acquisition or AIDS outcomes in vivo. This result contrasts with the known in vitro functional role of Siglec-1 in HIV-1 trans-infection. Thus, it provides evidence that the classical HIV-1 infectious routes may compensate for the lack of Siglec-1 in fuelling HIV-1 dissemination within infected individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions

  • Arimany-Nardi, Cristina
  • Minuesa, Gerard|||0000-0001-9911-8428
  • Keller, Thorsten
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Koepsell, Hermann
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
Lamivudine (3TC), a drug used in the treatment of HIV infection, needs to cross the plasma membrane to exert its therapeutic action. Human Organic cation transporter 1 (hOCT1), encoded by the SLC22A1 gene, is the transporter responsible for its uptake into target cells. As SLC22A1 is a highly polymorphic gene, the aim of this study was to determine how SNPs in the OCT1-encoding gene affected 3TC internalization and its interaction with other co-administered drugs. HEK293 cells stably transfected with either the wild type form or the polymorphic variants of hOCT1 were used to perform kinetic and drug-drug interaction studies. Protein co-immunoprecipitation was used to assess the impact of selected polymorphic cysteines on the oligomerization of the transporter. Results showed that 3TC transport efficiency was reduced in all polymorphic variants tested (R61C, C88R, S189L, M420del, and G465R). This was not caused by lack of oligomerization in case of variants located at the transporter extracellular loop (R61C and C88R). Drug-drug interaction measurements showed that co-administered drugs [abacavir (ABC), zidovudine (AZT), emtricitabine (FTC), tenofovir diproxil fumarate (TDF), efavirenz (EFV) and raltegravir (RAL)], differently inhibited 3TC uptake depending upon the polymorphic variant analyzed. These data highlight the need for accurate analysis of drug transporter polymorphic variants of clinical relevance, because polymorphisms can impact on substrate (3TC) translocation but even more importantly they can differentially affect drug-drug interactions at the transporter level.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Bilbao, Eneritz
  • Agulló, Luis
  • Marfil, Sílvia|||0000-0003-0139-5000
  • García Rodríguez, Elisabet
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Nieto-Garai, Jon A.
  • Contreras, F. Xabier
  • Floor, Martin
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Villà Freixa, Jordi|||0000-0002-6359-3929
  • Lorizate, Maier
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
The HIV-1 gp41 Membrane Proximal External Region (MPER) is recognized by broadly neutralizing antibodies and represents a promising vaccine target. However, MPER immunogenicity and antibody activity are influenced by membrane lipids. To evaluate lipid modulation of MPER immunogenicity, we generated a 1-Palmitoyl-2-oleoylphosphatidylcholine (POPC)-based proteoliposome collection containing combinations of phosphatidylserine (PS), GM3 ganglioside, holesterol (CHOL), sphingomyelin (SM) and the TLR4 agonist monophosphoryl lipid A (MPLA). A recombinant gp41-derived miniprotein (gp41-MinTT) exposing the MPER and a tetanus toxoid (TT) peptide that favors MHC-II presentation, was successfully incorporated into lipid mixtures (.